GIC acquires stake in ADICON HOLDINGS (09860) and AI medical strategy undertaken with "Patient Capital" deeply anchored.

On January 26, the healthcare testing sector of the Hong Kong stock market saw a major capital move. The internationally renowned investment firm GIC Private Limited increased its stake in ADICON HOLDINGS (09860) by 891,500 shares, at a price of 5 Hong Kong dollars per share, for a total amount of 4.4575 million Hong Kong dollars. After the increase, the latest number of shares held is 36.8375 million shares, with a stake of 5.07%, officially triggering the take-over threshold. It is worth noting that ADICON's strategic layout in the field of AI medical testing has received widespread attention in the market recently. By standing on the node of AI technology accelerating the reconstruction of the medical system, ADICON is actively promoting the evolution of medical testing services from traditional modes to intelligent and ecological modes. In December last year, the company signed a cooperation agreement with Huawei Cloud to jointly open a new chapter of smart healthcare powered by AI technology, showcasing ADICON's technological iteration path and forward-looking layout in the field of AI medical innovation. In November 2025, ADICON announced the acquisition of Crown Bioscience for a maximum price of 204 million US dollars. Crown is a leader in AI deployment in the field, with the industry's first pre-clinical data platform and advanced collaborative anti-cancer drug prediction tools. This acquisition will significantly strengthen the company's comprehensive strength in drug research and diagnostic value chain. In response to this, FuRui Financial issued a research report, giving ADICON HOLDINGS (09860) a "buy" rating with a target price of 12.60 Hong Kong dollars. The firm mentioned that ADICON's strategic layout in the field of AI medical testing and the major move to acquire Crown Bioscience will significantly enhance the company's comprehensive strength in the drug research and diagnostic value chain. Analysts point out that GIC's take-over this time is expected to have a demonstrative effect, driving ADICON's ecological expansion in the AI medical field and further consolidating its position as a top-quality asset in the industry.